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Abstract
Objective
To perform a systematic review of studies describing paediatric adverse drug reactions (ADRs)
conducted from national pharmacovigilance databases.
Methods
A systematic literature search of studies describing results for paediatric ADRs from national
pharmacovigilance databases was performed. PubMed database, Embase and MEDLINE were
searched up to March 2015. The descriptive studies included were analysed for country of origin,
reporters, and ADR reporting rate, drugs, ADRs and number of fatalities.
Results
20 studies were identified. Doctors were the largest group of reporters in all the studies, and with more
consumer reports seen in USA. The studies ranged from 3 – 37 years. The highest ADR reporting rate
was 1458 reports per year per million children in Cuba. Antibiotics and vaccines were the most
frequently reported drugs, in almost all the studies. The most frequent ADRs were skin and nervous
system disorders. The highest proportion of fatalities and serious reports was from North America.
Drugs used for treating attention deficit hyperactivity disorders (ADHD) and isotretinoin were the
most frequently reported drugs for ADRs in North America.
Conclusions
There were geographical differences in drugs responsible for ADRs and their seriousness, especially
in North America. Very few studies were conducted in Asia and Latin America, none were found from
Africa.
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INTRODUCTION
Adverse drug reactions (ADRs) are a major problem for children in all countries [1].
One in ten children in hospital in a high income country (HIC) will experience an
ADR [2]. A study in Cuba suggested that at least one in 500 children will experience
an ADR each year [3]. National pharmacovigilance databases have been useful in
detecting signals. They have also been helpful in describing the type of ADRs
experienced by children in a country and the drugs responsible [4]. The majority of the
published studies describing ADR data for children have originated from HICs in
Europe. The most frequently described ADRs in children in Europe are rashes,
headache, pyrexia and gastrointestinal disorders. The medicines responsible were
antibiotics and vaccines.
Antibiotics and vaccines are the most widely used medicines in children worldwide.
However, there are significant differences in the use of antibiotics in different
countries. Additionally, there are major differences in the use of medicines in
children, even in Europe [5, 6]. Therefore, one may see differences in the types of
ADRs experienced. Additionally, the prevalence of diseases will be different in low
income (LIC) and lower middle income countries (LMIC). One would therefore
expect the ADRs to be different. Antimalarials for example are infrequently used in
children in Europe. Many ADRs are preventable due to inappropriate prescribing. It
is only by identifying the drugs responsible for ADRs that one can determine areas
where prescribing may be inappropriate. We therefore decided to look at all
publications reporting ADRs in children from national pharmacovigilance databases
3to explore the differences between ADRs and drugs responsible in different
countries.
METHODS
A systematic literature search of published studies describing ADRs from national
spontaneous reporting pharmacovigilance databases was performed. In order to
capture the relevant articles, the following terms and/or keywords assigned to articles
which studied ADRs from databases were used: adverse drug reaction*, adverse
effect*, adverse event* side effect*, pharmacovigilance, spontaneous reporting,
adverse drug reaction reporting system, adverse drug reaction reporting, drug
surveillance program and adverse event reporting. The databases used were PubMed,
Embase and MEDLINE. The PubMed database was searched from when the WHO
Collaborating Centre for International Drug Monitoring in Uppsala was established
in 1978 to March 2015. The WHO centre receives individual case safety reports of
suspected ADRs from national pharmacovigilance centres around the world [7].
Embase and MEDLINE were searched from 1980 to March 2015 and 1947 to March
2015 respectively. In addition to these searches, the reference lists of publications
were also searched. The search strategy is as shown below in Table 1.
Articles which described ADRs from national, international or regional
pharmacovigilance databases were considered. Studies describing specific ADRs and
drugs, vaccines, specific treatments and procedures for disease conditions in
pharmacovigilance databases were excluded. All ADR studies outside of national,
international or regional pharmacovigilance databases were also excluded.
All the included articles were considered by country of study, population, duration of
study, number of patients/reports, notifiers, types of drugs and ADRs, death reports,
4and whether the data used for the studies were from a regional, national or
international ADR database. The articles identified were separated into those
reporting on the general population and paediatric population. Only the paediatric
studies were analysed.
The ADR reporting rate for studies where this was not reported was calculated as
follows:
[Reporting rate = annual average number of reports/population X 1 million]
The population estimates were taken from United Nations Population Division,
World Population Prospects: The 2012 Revision [8].
RESULTS
The literature search produced a total of 6720 articles from PubMed, Embase and
MEDLINE. When the inclusion and exclusion criteria were applied, 41articles were
identified, made up of 20 for paediatric studies and 21 for general population studies
(Figure 1). Only the 20 paediatric studies were analysed.
Summary of findings
The 20 studies reviewed included 3 international, 12 national and 5 regional studies.
The majority of the studies were conducted in Europe. Four were from North
America, two from Latin America, one from Asia and none from Africa.
Eight of the studies excluded vaccines (including all four from North America)
(Table 2). The majority of the studies grouped ADRs in system organ class (SOC)
and suspect drugs in anatomical therapeutic class (ATC) or drug class, and presented
them in percentages of first, second and third most frequently reported. The type of
notifiers and death reports were also presented in percentages.
5The period of time data was collected for the studies ranged from 3 – 37 years. The
37-year data described fatal suspected ADRs in UK between 1964 and 2000. For the
studies which described seriousness of the events, the percentages of ADRs or
reports ranged between 2 – 68% of the total number of ADRs or reports. The highest
proportion of serious reports was from North America (42 – 62%). Four studies
described reporting rates. The reporting rates for the other studies were calculated
using an estimate of the childhood population for the year of study. The highest ADR
reporting rates of 634 and 1458 reports per year per million children were described
in regional studies conducted in Cuba in 2010 and 2012 respectively.
Nine studies described notifiers of ADRs (Table 3). Doctors were the largest group of
reporters in eight of the studies. Pharmacists and other HCPs (including nurses) also
submitted reports in most countries. The largest proportion of reports from
consumers was from the USA.
Reported ADRs
The majority of the studies reported skin disorders (rash and urticaria) as the most
frequent ADRs (Table 4). Other common ADRs were nervous system disorders
(headache, dizziness and drowsiness), and pyrexia/fever. The less commonly
reported ADRs were convulsions, diarrhoea and agitation. One study [19] described
only fatal reports, and the most frequent fatal ADR in this study was hepatic failure.
The majority of the studies which ranked the frequency of ADRs described them in
system organ class. Only a few studies described ADRs in lowest level terms.
Reported drugs
The most frequently reported drugs are shown in Table 5. Antibiotics and vaccines
were the most frequently reported drugs in almost all the studies identified in Europe,
6Latin America and Asia. Amoxicillin was the most frequently reported individual
antibiotic (where this was stated) apart from in one Italian study where it was second
after amoxicillin/clavulanic acid and in one Chinese study where cefuroxime was the
most frequent.
In contrast, in North America, drugs used for treating attention deficit hyperactivity
disorders (methylphenidate was named in one study) and isotretinoin were most
frequently reported. There was no uniformity in the way frequency of drugs reported
were described in the studies. In most studies, anatomic therapeutic class were used
and in others, specific drugs were described.
Deaths reported
The studies conducted in North America reported the highest fatality rates, which
ranged from 3.4 – 13.0% (Table 6). These rates contrasted sharply with the rates
reported in Europe, which ranged between 0.1 – 2.2% with a mean rate of 0.8%. In
the UK study [19] which described 37-year data, 0.8% fatality was recorded.
DISCUSSION
Systemic anti-infectives and vaccines were the group of drugs most frequently
associated with ADRs in studies in Europe, Asia and Latin America. This reflects the
widespread use of anti-infectives and vaccines in children [27, 28]. Many anti-
infectives, however, are prescribed inappropriately [5, 6]. Reducing inappropriate
prescribing would reduce the number of ADRs. In contrast, in North America [21-23],
drugs used for treating attention deficit hyperactivity disorders (ADHD) and
isotretinoin were most often associated with the ADRs. These findings suggest that
the epidemiology of the use of medicines in children in North America may be
different to other countries. The diagnosis of ADHD in children visiting outpatient
clinics in USA has been on the rise since 2000 [29]. Interestingly, antiepileptic drugs
7were the third most frequently reported group of drugs in most countries, including
North America.
The most frequently reported ADRs were skin disorders and pyrexia. The proportions
of deaths in the reports were higher in North America compared with those in
Europe, Asia and Latin America. This may reflect differences in the use of medicines
and also differences in attitudes towards reporting. This is an area open to further
research.
The countries which have established programmes of ADR reporting in their
healthcare system are likely to have more reports in national ADR databases. The
size of the country, population and duration of time of data collected for the study
may also influence the number of reports in the database. The combination of these
factors may have contributed to the higher number of reports or rates of reporting per
population observed in the national studies conducted in UK [14, 19], Denmark [15],
Sweden [16] and USA [21, 24]. The high reporting rates recorded from the studies in a
regional ADR database in Cuba [3, 25] was attributed to a special educational
programme on pharmacovigilance for healthcare professionals. The high number of
reports received per year in these countries is an indication of success of the reporting
scheme.
Even though most of the studies in Europe and North America showed evidence of
efficient reporting scheme, not all the HPCs were actively engaged in reporting
ADRs. The results showed physicians and doctors submitted more reports than
pharmacists and nurses. Other HPCs, especially nurses, could be encouraged by
giving them focussed education to detect and report ADRs [30], due to their unique
role in observing patients’ signs and symptoms. This approach has been successful in
Sweden [31] and Latin America [25].
8This study has several limitations. Very few studies were conducted in Asia and
Latin America, therefore, comparison of reported ADRs and drugs between the
continents was not possible. No study was identified from Africa. Since the search
was performed, however, we have published two studies describing ADR reports for
children in Nigeria and Ghana [32, 33]. There was no uniformity in the reports in terms
of ADRs and drugs description. Authors described ADRs and drugs differently in the
studies. Some of the studies described ADRs in system organ class and others in
lowest level reaction terms. The drugs were also described differently in anatomical
therapeutic class and specific drugs/active substances. All these made comparison of
the studies difficult.
CONCLUSIONS
The majority of the studies reviewed were from Europe and North America, no study
was identified from Africa. ADR reporting rates are higher in Europe, North America
and Latin America compared to Asia. Physicians and doctors reported more ADRs
compared to pharmacists and nurses.
Vaccines and anti-infectives were most frequently associated with ADRs in children,
with the exception of North America. The reported fatality rate was higher in North
America.
Expert Opinion
ADRs are under-reported world-wide. The highest reporting rate was 1458 reports
per year per million children in Cuba. Reporting rates in Europe (the continent with
most studies) were considerably lower. Education about ADRs and their reporting is
needed in Europe. Antibiotics and vaccines were the most frequently reported groups
of drugs in most studies. They are also the most frequently prescribed groups of
9drugs to young children. Antibiotics are often prescribed inappropriately and efforts
to improve rational prescribing are needed. In contrast in North America, drugs for
ADHD were the most frequently reported drugs. This may be related to the
widespread use of these drugs in North America. More reports of pharmacovigilance
are needed from low and middle income countries in Africa, Asia and Latin America.
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1TABLES
Table 1: Search strategy for articles
Database Step Search Terms
PubMed 1 Adverse drug reaction*
2 Adverse effect*
3 Side effect*
4 1 OR 2 OR 3
5 Pharmacovigilance
6 Spontaneous reporting
7 Adverse drug reaction reporting system
8 5 OR 6 OR 7
9 4 AND 8
Embase/MEDLINE 1 Adverse drug reaction*
2 Adverse effect*
3 Adverse event*
4 Side effect*
5 1 OR 2 OR 3 OR 4
6 Pharmacovigilance
7 Drug surveillance program
8 Adverse drug reaction reporting
9 Adverse event reporting
10 6 OR 7 OR 8 OR 9
11 5 AND 10
2Table 2: Type of study and Annual reporting frequency
Author/continent Country Children
Population
(years)
Study
duration
(years)
Number
of
reports
Percentage of
serious
reports/ADRs
Population
estimate*
ADR
reporting
rate
Source of data/
description of reports
International
Aagaard et al. 2014 [9] International ≤ 17 5 240 68 2.2 billion 0.02 VigiBase 
(Consumer reports)
Star et al. 2011 [7] International ≤ 17 10 268145 - 2.2 billion 12 VigiBase (Vaccines excluded) 
Europe
Blake et al. 2014 [10] International < 18 18.5 279359 - 742.8 million 20 EudraVigilance
(European study)
Ferrajolo et al. 2014 [11] Italy < 18 12 8338 39 10.3 million 67 National study (Vaccines excluded)
Carnovale et al. 2014 [12] Italy ≤ 17 4 3539 17 10.3 million 86 Regional study 
Aldea et al. 2012 [13] Spain ≤ 17 6 4279 37 8.4 million 85 National study 
Hawcutt et al. 2012 [14] UK < 17 10 31726 - 13.3 million 238 National study
Aagaard et al. 2010 [15] Denmark ≤ 17 10 2437 42 **1.1 million **222 National study
Kimland et al. 2005 [16] Sweden ≤ 15 15 5771 13 **1.7 million **226 National study
Schirm et al. 2004 [17] Netherlands ≤ 16 7 773 7 3.6 million 31 National study (Vaccines excluded) 
Clarkson et al. 2004 [18] UK ≤ 16 3 456 33 13.2 million 11 Regional study 
Clarkson et al. 2002 [19] UK ≤ 14 37 43755 - 11.0 million 107 National study (Vaccines excluded) 
(Fatal ADR reports only)
Morales-Olivas et al. 2000 [20] Spain ≤ 14 10 1419 27 5.9 million 24 National study 
North America
Lee et al. 2014 [21] USA < 18 5.7 78623 42 75.2 million 183 National study (Vaccines excluded)
Johann-Liang et al. 2009 [22] USA < 18 5 36241 62 75.1 million 97 National study (Vaccines excluded)
Carleton et al. 2007 [23] Canada ≤ 19 4.5 1193 61 7.0 million 38 National study (Vaccines excluded) 
Moore et al. 2002 [24] USA < 2 3 5976 61 7.8 million 255 National study (Vaccines excluded)
children < 2 years
Latin America
Arencibia et al. 2012 [3] Cuba ≤ 18 2 533 31 **183,105 **1458 Regional study
Arencibia et al. 2010 [25] Cuba ≤ 18 1 124 15 **195,504 **634 Regional study
Asia
Li et al. 2014 [26] China ≤ 17 1 3848 2 301.2 million 13 Regional study 
*Population estimates were taken from United Nations Population Division, World Population Prospects: The 2012 Revision [8] to calculate the reporting rates
**Population and rate as reported in study
3Table 3: Notifiers of reports
Author/Continent Country Physicians/doctors
(%)
Pharmacists
(%)
Nurses and
other HCPs
(%)
Consumers
(%)
Comments
Star et al. 2011 [7] International 55 3 3 4 VigiBase reports
Europe
Ferrajolo et al. 2014 [11] Italy 83 10 6 1 National
Aldea et al. 2012 [13] Spain 63 11 24 - National
Hawcutt et al. 2012 [14] UK 35 5 59 1 National
Aagaard et al. 2010 [15] Denmark 89 1 7 4 National
Latin America
Arencibia et al. 2012 [3] Cuba 73 15 10 1 Regional
Arencibia et al. 2010 [25] Cuba 60 16 24 - Regional
Asia
Li et al. 2014 [26] China 52 24 16 3 Regional
North America
Lee et al. 2014 [21] USA 31 6 22 31 National
4Table 4: Most frequently reported ADRs
Author/continent Country 1st most frequent ADR 2nd most frequent ADR 3rd most frequent ADR Comments
International
Aagaard et al. 2014 [9] International General disorders (20%) Nervous system disorders (14%) Injury, poison & proc compl (7%) VigiBase data
Star et al. 2011 [7] International Skin disorders (35%) General disorders (20%) Nervous system disorders (19%) VigiBase data
Europe
Blake et al. 2014 [10] International Pyrexia (13%) Vomiting (6%) Convulsion (4%) EudraVigilance
data
Ferrajolo et al. 2014 [11] Italy Skin disorders (52%) Gastrointestinal disorders (17%) Nervous system disorders (12%)
Carnovale et al. 2014 [12] Italy Skin disorders (26%) General disorders (24%) Gastrointestinal disorders (11%)
Aldea et al. 2012 [13] Spain Pyrexia (7%) Application site reaction (4%) Urticaria (3%)
Hawcutt et al. 2012 [14] UK Headache (10%) Dizziness (9%) Pyrexia (7%)
Aagaard et al. 2010 [15] Denmark General disorders (31%) Skin disorders (18%) Nervous system disorders (15%)
Kimland et al. 2005 [16] Sweden Application site reaction (24%) Fever (12%) Rash (Exanthema) (7%)
Schirm et al. 2004 [17] Netherlands Tooth discolouration (6%) Rash (5%) Agitation (3%)
Clarkson et al. 2004 [18] UK Not reported Not reported Not reported
Morales-Olivas et al. 2000
[20]
Spain Rash (18%) Urticaria (6%) Diarrhoea (5.7%)
North America
Lee et al. 2014 [21] USA Not reported Not reported Not reported
Johann-Liang et al. 2009
[22]
USA Not reported Not reported Not reported
Carleton et al. 2007 [23] Canada Not reported Not reported Not reported
Moore et al. 2002 [24] USA Not reported Not reported Not reported
Latin America
Arencibia et al. 2012 [3] Cuba Urticaria/angioedema (29%) Drowsiness (11%) Vomiting (9%)
Arencibia et al. 2010 [25] Cuba Drowsiness (14%) Headache (11%) Respiratory distress/failure (10%)
Asia
Li et al. 2014 [26] China Rash (Exanthema) (29%) Fever (21%) Application site reaction (9%)
5Table 5: Most frequently reported drugs
Author/
continent
Country 1st most frequent
drug
2nd most frequent drug 3rd most frequent
drug
4th most frequent
drug
5th most frequent
drug
Comments
International
Aagaard et al.
2014 [9]
International Anti-infectives and
vaccines
(36%)
Antineoplastic
agents (23%)
Sex hormones
(13%)
Nervous system
(12%)
Respiratory
system (2%)
VigiBase
Star et al.
2011 [7]
International Amoxicillin
(33%)
Atomoxetine
(28%)
Dermatologicals
(12%)
Respiratory
system (11%)
Alimentary tract & metabolism
(10%)
VigiBase
Europe
Blake et al.
2014 [10]
International Vaccines Isotretinoin Methylphenidate Etanercept Paracetamol Eudra-
Vigilance
Ferrajolo et al.
2014 [11]
Italy Amoxicillin/
clavulanic acid
Amoxicillin Ibuprofen Paracetamol Clarithromycin Reports exclude
vaccines
Carnovale et al.
2014 [12]
Italy Vaccines
(37.5%)
Antibacterials
(21.6%)
Antineoplastic
agents (9.5%)
Psycholeptics
(6.7%)
Anti-inflammatory
(5.0%)
Aldea et al.
2012 [13]
Spain Vaccines Methylphenidate Respiratory system Not reported
Hawcutt et al.
2012 [14]
UK Vaccines
(74.4%)
ADHD medication
(3.7%)
Anti-epileptics
(3.1%)
Anti-infectives
(2.5%)
Immunosuppressants
(2.3%)
Aagaard et al.
2010 [15]
Denmark Vaccines
(61.1%)
Antidepressants
(6.9%)
Antiepileptics
(4.0%)
Allergens
(3.0%)
Antipsychotics
(2.6%)
Kimland et al.
2005 [16]
Sweden Vaccines
(63.8%)
Antibacterials
(10.1%)
Antiasthmatics
(4.9%)
Antiepileptics
(3.1%)
Not reported
Schirm et al.
2004 [17]
Netherlands Amoxicillin
(5%)
Salbutamol
(3.2%)
Clarithromycin
(2.8%)
Methylphenidate
(2.7%)
Fluticasone
(2.7%)
Clarkson et al.
2004 [18]
UK Vaccines
(34.7%)
Topical
local anaesthetics (17.2%)
Anticonvulsants
(11.0%)
Antibiotics
(9.1%)
Cytotoxics&immunosupressant
s (5.5%)
Clarkson et al.
2002 [19]
UK Anticonvulsants
(20.0%)
Cytotoxics
(10.8%)
Antibiotics
(7.9%)
Anaesthetics-
intravenous (5.1%)
Anaesthetics-inhaled (4.4%) Fatal
reports only
Morales-Olivas
et al. 2000 [20]
Spain Vaccines
(12.9%)
Amoxicillin
(8.5%
Erythromycin
(3.7%)
Cotrimoxazole
(3.0%)
Acetylsalicylic acid (2.7%)
6Table 5: Most frequently reported drugs continued
Author/continent Country 1st most frequent
drug
2nd most frequent
drug
3rd most frequent
drug
4th most frequent
drug
5th most frequent
drug
Comments
North America
Lee et al.
2014 [21]
USA Methylphenidate
(3.5%)
Montelukast
(1.9%)
Ibuprofen
(1.5%)
Lisdexamfetamine
(1.3%)
Somatropin
(1.2%)
Children 1 to <12 years
Lee et al.
2014 [21]
USA Isotretinoin
(3.2%)
Infliximab
(2.8%)
Drospironone&ethin
ylestradiol (1.7%)
Methylphenidate
(1.6%)
Adalimumab
(1.3%)
Children 12 to <18 years
Johann-Liang et al.
2009 [22]
USA ADHD drugs Anticonvulsants Antidepressants Antipsychotics Chemotherapeutics
Carleton et al.
2007 [23]
Canada Isotretinoin
(3.8%)
Paroxetine
(2.9%)
Methylphenidate
(2.8%)
Amoxicillin
(2.7%)
Valproic acid
(2.2%)
Moore et al.
2002 [24]
USA Palivizumab
(27.9%)
Cisapride
(4.0%)
Indomethacin
(3.8%)
Nitric oxide
(3.4%)
Azithromycin
(2.1%)
Only drugs associated with
serious or fatal outcome;
children < 2 years
Latin America
Arencibia et al.
2012 [3]
Cuba Vaccines Antibiotics Antihistamines Analgesics
(nonopioid)
Bronchodilators
Arencibia et al.
2010 [25]
Cuba Antibiotics
(32%)
Vaccines
(15%)
Analgesics
(14%)
ACE inhibitors
(6%)
Bronchodilators
(6%)
Asia
Li et al.
2014 [26]
China Vaccines
(42.2%)
Cefuroxime
(9.9%)
Azithromycin
(8.8%)
Cefotiam
(3.4%)
Not reported
7Table 6: Death reports
Author/continent Country Number of
reports
Number
of deaths
Proportion of
deaths (%)
Comments on
type of data
International
Aagaard et al.
2014 [9]
International 240 3 1.3 VigiBase
(Consumer reports)
Europe
Ferrajolo et al.
2014 [11]
Italy 8338 28 0.3
Aldea et al.
2012 [13]
Spain 4279 33 0.8
Aagaard et al.
2010 [15]
Denmark 2437 28 1.1
Kimland et al.
2005 [16]
Sweden 5771 8 0.1
Clarkson et al.
2004 [18]
UK 456 10 2.2
Clarkson et al.
2002 [19]
UK 43755 331 0.8 Fatal ADR reports
only (37-year data)
Morales-Olivas et al.
2000 [20]
Spain 1419 4 0.3
North America
Lee et al. 2014 [21] USA 78623 6290 8.0
Johann-Liang et al.
2009 [22]
USA 36241 2901 8.0
Carleton et al.
2007 [23]
Canada 1193 41 3.4
Moore et al.
2002 [24]
USA 7111 769 13.0 3-year data
Latin America
Arencibia et al.
2012 [3]
Cuba 533 1 0.2
Arencibia et al.
2010 [25]
Cuba 124 2 1.6
Asia
Li et al. 2014 [26] China 3848 13 0.3
